Cargando…

Alleviation of Pseudomonas aeruginosa Infection by Propeptide-Mediated Inhibition of Protease IV

Pseudomonas aeruginosa, an opportunistic human pathogen, expresses protease IV (PIV) for infection. Since the PIV activity can be inhibited by its propeptide, we tried to alleviate the severity of P. aeruginosa infection using the purified PIV propeptide (PIV(pp)). The PIV(pp) treatment of P. aerugi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Tae-Hyeon, Li, Xi-Hui, Lee, Joon-Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549743/
https://www.ncbi.nlm.nih.gov/pubmed/34704789
http://dx.doi.org/10.1128/Spectrum.00782-21
_version_ 1784590830208548864
author Kim, Tae-Hyeon
Li, Xi-Hui
Lee, Joon-Hee
author_facet Kim, Tae-Hyeon
Li, Xi-Hui
Lee, Joon-Hee
author_sort Kim, Tae-Hyeon
collection PubMed
description Pseudomonas aeruginosa, an opportunistic human pathogen, expresses protease IV (PIV) for infection. Since the PIV activity can be inhibited by its propeptide, we tried to alleviate the severity of P. aeruginosa infection using the purified PIV propeptide (PIV(pp)). The PIV(pp) treatment of P. aeruginosa could significantly inhibit the PIV activity and reduce the virulence of P. aeruginosa in multiple invertebrate infection models, such as nematodes, brine shrimp, and mealworms. The effectiveness of PIV(pp) was further confirmed using mouse skin infection and acute/chronic lung infection models. The amount of PIV(pp) that inhibited the PIV activity of P. aeruginosa by 65% could alleviate the severity of infection significantly in all of the skin and acute/chronic lung infections. In addition, the PIV(pp) treatment of P. aeruginosa facilitated the healing of the skin wound infections and repressed the growth of P. aeruginosa in the infected lung. The PIV(pp) itself did not cause the induction of inflammatory cytokines or have any harmful effects on host tissues and did not affect bacterial growth. Taken together, P. aeruginosa infections can be alleviated by PIV(pp) treatment. IMPORTANCE Pseudomonas aeruginosa is a highly antibiotic-resistant pathogen and is extremely difficult to treat. Instead of using conventional antibiotics, we attempted to alleviate P. aeruginosa infection using factors that P. aeruginosa itself produces naturally. Extracellular proteases are powerful virulence factors and important targets to control the P. aeruginosa infections. Propeptides are originally expressed as part of extracellular proteases, inhibiting their activity until they go out of the cell, preventing them from becoming toxic to the cells themselves. We confirmed, from multiple animal experiments, that treating P. aeruginosa with the purified propeptide can alleviate its infectivity. Propeptides specifically inhibit only their cognate protease without inhibiting other essential proteases of the host. The development of resistance can be avoided because the propeptide-mediated inhibition is an inherent mechanism of P. aeruginosa; hence, it will be difficult for P. aeruginosa to alter this mechanism. Since propeptides do not affect bacterial growth, there is no selective pressure to develop resistant cells.
format Online
Article
Text
id pubmed-8549743
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-85497432021-11-08 Alleviation of Pseudomonas aeruginosa Infection by Propeptide-Mediated Inhibition of Protease IV Kim, Tae-Hyeon Li, Xi-Hui Lee, Joon-Hee Microbiol Spectr Research Article Pseudomonas aeruginosa, an opportunistic human pathogen, expresses protease IV (PIV) for infection. Since the PIV activity can be inhibited by its propeptide, we tried to alleviate the severity of P. aeruginosa infection using the purified PIV propeptide (PIV(pp)). The PIV(pp) treatment of P. aeruginosa could significantly inhibit the PIV activity and reduce the virulence of P. aeruginosa in multiple invertebrate infection models, such as nematodes, brine shrimp, and mealworms. The effectiveness of PIV(pp) was further confirmed using mouse skin infection and acute/chronic lung infection models. The amount of PIV(pp) that inhibited the PIV activity of P. aeruginosa by 65% could alleviate the severity of infection significantly in all of the skin and acute/chronic lung infections. In addition, the PIV(pp) treatment of P. aeruginosa facilitated the healing of the skin wound infections and repressed the growth of P. aeruginosa in the infected lung. The PIV(pp) itself did not cause the induction of inflammatory cytokines or have any harmful effects on host tissues and did not affect bacterial growth. Taken together, P. aeruginosa infections can be alleviated by PIV(pp) treatment. IMPORTANCE Pseudomonas aeruginosa is a highly antibiotic-resistant pathogen and is extremely difficult to treat. Instead of using conventional antibiotics, we attempted to alleviate P. aeruginosa infection using factors that P. aeruginosa itself produces naturally. Extracellular proteases are powerful virulence factors and important targets to control the P. aeruginosa infections. Propeptides are originally expressed as part of extracellular proteases, inhibiting their activity until they go out of the cell, preventing them from becoming toxic to the cells themselves. We confirmed, from multiple animal experiments, that treating P. aeruginosa with the purified propeptide can alleviate its infectivity. Propeptides specifically inhibit only their cognate protease without inhibiting other essential proteases of the host. The development of resistance can be avoided because the propeptide-mediated inhibition is an inherent mechanism of P. aeruginosa; hence, it will be difficult for P. aeruginosa to alter this mechanism. Since propeptides do not affect bacterial growth, there is no selective pressure to develop resistant cells. American Society for Microbiology 2021-10-27 /pmc/articles/PMC8549743/ /pubmed/34704789 http://dx.doi.org/10.1128/Spectrum.00782-21 Text en Copyright © 2021 Kim et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Kim, Tae-Hyeon
Li, Xi-Hui
Lee, Joon-Hee
Alleviation of Pseudomonas aeruginosa Infection by Propeptide-Mediated Inhibition of Protease IV
title Alleviation of Pseudomonas aeruginosa Infection by Propeptide-Mediated Inhibition of Protease IV
title_full Alleviation of Pseudomonas aeruginosa Infection by Propeptide-Mediated Inhibition of Protease IV
title_fullStr Alleviation of Pseudomonas aeruginosa Infection by Propeptide-Mediated Inhibition of Protease IV
title_full_unstemmed Alleviation of Pseudomonas aeruginosa Infection by Propeptide-Mediated Inhibition of Protease IV
title_short Alleviation of Pseudomonas aeruginosa Infection by Propeptide-Mediated Inhibition of Protease IV
title_sort alleviation of pseudomonas aeruginosa infection by propeptide-mediated inhibition of protease iv
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549743/
https://www.ncbi.nlm.nih.gov/pubmed/34704789
http://dx.doi.org/10.1128/Spectrum.00782-21
work_keys_str_mv AT kimtaehyeon alleviationofpseudomonasaeruginosainfectionbypropeptidemediatedinhibitionofproteaseiv
AT lixihui alleviationofpseudomonasaeruginosainfectionbypropeptidemediatedinhibitionofproteaseiv
AT leejoonhee alleviationofpseudomonasaeruginosainfectionbypropeptidemediatedinhibitionofproteaseiv